Systematic Review of Xuezhikang Capsules Combined with Statins in the Treatment of Hyperlipidemia

YANG Ping; SHU Xiangbing; LIU Hua; BAI Huanhuan; GOU Xiaojun; WU Yan; WANG Zhuoyuan

doi:10.14009/j.issn.1672-2124.2021.03.015

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Xuezhikang Capsules Combined with Statins in the Treatment of Hyperlipidemia

更新时间：2022-10-08

- Systematic Review of Xuezhikang Capsules Combined with Statins in the Treatment of Hyperlipidemia
- Vol. 21, Issue 3, Pages: 319-323(2021)
- 作者机构：
  
  1. 苏州大学附属第二医院营养科
  2. 上海市宝山区中西医结合医院中心实验室
  3. 陕西中医药大学药学院
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.03.015
  CLC： R589.2
- Published：2021，
扫描看全文
[1]杨萍,舒详兵,刘华,白换换,苟小军,吴嫣,王卓媛.血脂康胶囊联合他汀类药物治疗高脂血症的系统评价[J].中国医院用药评价与分析,2021,21(03):319-323+328.

YANG Ping, SHU Xiangbing, LIU Hua, et al. Systematic Review of Xuezhikang Capsules Combined with Statins in the Treatment of Hyperlipidemia. [J]. 21(3):319-323(2021)
[1]杨萍,舒详兵,刘华,白换换,苟小军,吴嫣,王卓媛.血脂康胶囊联合他汀类药物治疗高脂血症的系统评价[J].中国医院用药评价与分析,2021,21(03):319-323+328. DOI： 10.14009/j.issn.1672-2124.2021.03.015.

YANG Ping, SHU Xiangbing, LIU Hua, et al. Systematic Review of Xuezhikang Capsules Combined with Statins in the Treatment of Hyperlipidemia. [J]. 21(3):319-323(2021) DOI： 10.14009/j.issn.1672-2124.2021.03.015.

摘要

目的:系统评价血脂康胶囊联合他汀类药物治疗高脂血症的临床疗效。方法:通过计算机检索PubMed、Cochrane图书馆、中国知网、万方数据库和维普数据库

检索建库至2020年12月血脂康胶囊治疗高脂血症相关文献

纳入随机对照试验（randomized controlled trial

RCT）文献（研究组患者服用血脂康胶囊联合他汀类药物

对照组患者单独服用他汀类药物）

采用纽卡斯尔-渥太华量表（Newcastle-Ottawa scale

NOS）进行文献质量评价

提取血脂水平甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）及低密度脂蛋白胆固醇（LDL-C）的参数

应用Rev Man 5.3软件进行荟萃分析（Meta分析）、敏感性分析及发表偏倚检测。结果:共纳入11篇符合标准的RCT文献

总病例数为1 559例

研究组782例

对照组777例;其中6篇文献提及不良反应。Meta分析结果显示

研究组患者的总有效率明显高于对照组（OR=3.60

95%CI=2.56～5.07

Z=7.33

P<0.000 01

I2=0%<50%）

TC（MD=-0.58

95%CI=-0.66～-0.50

Z=14.23

P<0.000 01

I2=49%<50%）、TG（MD=-0.24

95%CI=-0.28～-0.20

Z=11.39

P <0.000 01

I2=46%<50%）和LDL-C （MD=-0.40

95%CI=-0.45～-0.35

Z=14.54

P <0.000 01

I2=48%<50%）等指标水平明显低于对照组

HDL-C水平明显高于对照组（MD=0.23

95%CI=0.20～0.26

Z=16.13

P <0.000 01

I2=44%<50%）

不良反应发生率明显低于对照组（OR=0.41

95%CI=0.19～0.91

Z=2.19

P<0.03

I2=5%<50%）

上述差异均有统计学意义。结论:血脂康胶囊联合他汀类药物治疗高脂血症的综合疗效以及不良反应发生情况优于单独使用他汀类药物

在降低TG、TC、LDL-C和升高HDL-C方面的效果明显优于单独使用他汀类药物。

Abstract

OBJECTIVE: To systematically evaluate the clinical efficacy of Xuezhikang capsules combined with statins in the treatment of hyperlipidemia.METHODS: PubMed

the Cochrane Library

CNKI

Wanfang database and VIP database were retrieved to collect the randomized controlled trial（ RCT） of Xuezhikang capsules combined with statins in the treatment of hyperlipidemia（ the study group was given Xuezhikang capsules combined with statins

while the control group received statins）.The retrieval time was from the establishment of the database to Dec.2020.Newcastle-Ottawa scale（ NOS） was used to evaluate the quality of the literature.Parameters of triglyceride（ TG）

total cholesterol（ TC）

high density lipoprotein cholesterol（ HDL-C） and low density lipoprotein cholesterol（ LDL-C）were extracted.RevMan5.3 software was used for Meta-analysis

sensitivity analysis and publication bias detection.RESULTS: A total of 11 literature that met the criteria were included

with a total of 1 559 cases

including 782 cases in the study group and 777 cases in the control group.Adverse drug reactions were mentioned in 6 literature.Metaanalysis showed that the total effective rate of the study group was significantly higher than that of the control group（ OR = 3.60

95%CI= 2.56-5.07

Z = 7.33

0.000 01

= 0%

50%）

the levels of TC（ MD =-0.58

95% CI =-0.66--0.50

Z = 14.23

0.000 01

= 49%

50%）

TG（ MD =-0.24

95% CI =-0.28--0.20

Z = 11.39

0.000 01

= 46%

50%） and LDL-C（ MD =-0.40

95% CI =-0.45--0.35

Z = 14.54

0.000 01

= 48%

50%） and other indicators were significantly lower than those of the control group

the level of HDL-C was significantly higher than that of the control group（ MD = 0.23

95%CI = 0.20-0.26

Z = 16.13

0.000 01

= 44%

50%）

and the incidence of adverse drug reactions was significantly lower than that of the control group（ OR = 0.41

95%CI = 0.19-0.91

Z = 2.19

0.03

= 5%

50%）

with statistically significant differences.CONCLUSIONS:Xuezhikang capsules combined with statins in the treatment of hyperlipidemia has better comprehensive efficacy and lower incidence of adverse drug reactions than statins alone

and its effects in reducing TG

LDL-C and increasing HDL-C are significantly better than that of statins alone.

关键词

血脂康胶囊他汀类药物高脂血症Meta分析

Keywords

Xuezhikang capsulesStatinsHyperlipidemiaMeta-analysis

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Efficacy and Safety of Dantian Jiangzhi Pills Combined with Statins in the Treatment of Hyperlipidemia

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Systematic Review of Clinical Efficacy and Safety of Formula Granules of Liangfu Pill in the Treatment of Epigastric Pain

Systematic Review of Runzao Zhiyang Capsules Combined with Antihistamine in the Treatment of Chronic Urticaria

Related Author

LIU Wei

LI Xingxing

FAN Zongjing

CUI Jie

WU Yang

HE Wei

LI Ruyou

YANG Juan

Related Institution

Second School of Clinical Medicine, Beijing University of Chinese Medicine

Dept.of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine

Dept.of Geriatrics, Edong Healthcare Group Huangshi Central Hospital/Affiliated Hospital of Hubei Polytechnic University

Dept.of Respiratory Medicine, Edong Healthcare Group Huangshi Central Hospital/Affiliated Hospital of Hubei Polytechnic University

Dept.of Endocrine, the Second People’s Hospital of Yichang

⁰